Fusion protein · Agonist of Fas receptor (FAS) · developed by Allarity Therapeutics
APO010 is a recombinant fusion protein consisting of three human Fas ligand extracellular domains fused to the collagen domain of adiponectin, assembled into a hexameric structure. It acts as a Fas receptor agonist, activating the death receptor to trigger caspase-dependent apoptosis in tumor cells. It is studied in relapsed/refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03196947 | Phase 1/2 | Relapsed/Refractory Multiple Myeloma | Terminated | ALLR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Multiple Myeloma
Updated Oct 3, 2026. Something wrong or missing? Report it on the ALLR page.
See ALLR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ALLR catalysts and pipeline →